While there have been several preclinical trials that imply the utility of CB2 agonists in treating inflammatory lung disease, fibrosis, neurodegeneration, and cancer, the translation of those outcomes into humans remains difficult to elicit due to the differences in the physiological and pathological processes between the two models (Whiting et al., 2022; Carruthers and Grimsey, 2024). This evidence concerns the gene CNR2 and cancer.